

**CHMP5 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP18536b****Specification**

---

**CHMP5 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [O9NZZ3](#)**CHMP5 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 51510**Other Names**

Charged multivesicular body protein 5, Chromatin-modifying protein 5, SNF7 domain-containing protein 2, Vacuolar protein sorting-associated protein 60, Vps60, hVps60, CHMP5, C9orf83, SNF7DC2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CHMP5 Antibody (C-term) Blocking Peptide - Protein Information****Name** CHMP5**Synonyms** C9orf83, SNF7DC2**Function**

Probable peripherally associated component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I, -II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses) (PubMed:<a href="http://www.uniprot.org/citations/14519844" target="\_blank">14519844</a>). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release (PubMed:<a href="http://www.uniprot.org/citations/14519844" target="\_blank">14519844</a>).

target="\_blank">14519844</a>).

#### **Cellular Location**

Cytoplasm, cytosol. Endosome membrane; Peripheral membrane protein. Midbody. Note=Localizes to the midbody of dividing cells (PubMed:17853893). Localized in two distinct rings on either side of the Flemming body (PubMed:17853893)

#### **CHMP5 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **CHMP5 Antibody (C-term) Blocking Peptide - Images**

#### **CHMP5 Antibody (C-term) Blocking Peptide - Background**

CHMP5 belongs to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family. These proteins are components of ESCRT-III (endosomal sorting complex required for transport III), a complex involved in degradation of surface receptor proteins and formation of endocytic multivesicular bodies (MVBs). Some CHMPs have both nuclear and cytoplasmic/vesicular distributions, and one such CHMP, CHMP1A (MIM 164010), is required for both MVB formation and regulation of cell cycle progression (Tsang et al., 2006 [PubMed 16730941]).

#### **CHMP5 Antibody (C-term) Blocking Peptide - References**

Wang, H.R., et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(2):282-285(2008) Row, P.E., et al. J. Biol. Chem. 282(42):30929-30937(2007) Huang, H.H., et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15(4):738-742(2007) Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007) :Wang, H.R., et al. Oncology 71 (5-6), 423-429 (2006) :